» Articles » PMID: 19167087

Refractive, Topographic, Tomographic, and Aberrometric Analysis of Keratoconic Eyes Undergoing Corneal Cross-linking

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 2009 Jan 27
PMID 19167087
Citations 127
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To report refractive, topographic, tomographic, and aberrometric outcomes 12 months after corneal cross-linking (CXL) in eyes with progressive advanced keratoconus.

Design: Prospective, nonrandomized, single-center clinical study.

Participants: Twenty-eight eyes undergoing CXL between April and June 2006.

Intervention: Riboflavin-ultraviolet A (UVA)-induced CXL included instillation of 0.1% riboflavin-20% dextrane solution 30 minutes before UVA irradiation and every 5 minutes for an additional 30 minutes during irradiation.

Main Outcome Measures: Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), sphere and cylinder refraction, topography, tomography, aberrometry, and endothelial cell count were evaluated at baseline and at 1, 3, 6, and 12 months follow-up.

Results: Mean baseline UCVA and BSCVA were 0.17+/-0.09 and 0.52+/-0.17, respectively; 12-month mean UCVA and BSCVA were 0.27+/-0.08 and 0.72+/-0.16, a statistically significant difference (P<0.05). Mean spherical equivalent refraction showed a significant decrease of 0.41 diopters (D). Mean baseline simulated keratometry (SIM K) flattest and steepest meridians and SIM K average were 46.10, 50.37, and 48.08 D, respectively; at 12 months, 40.22, 44.21, and 42.01 D, respectively, were recorded, a difference that was significant for all 3 indices (P<0.05). Mean average pupillary power (APP) changed significantly from 47.50 to 41.04 D at 12 months (P<0.05) and apical keratometry (AK) from 58.94 to 55.18 D (P<0.05). The treated eyes showed no deterioration of the Klyce indices at 6 months postoperatively, whereas the untreated (contralateral) eyes did show deterioration. For a 3-mm pupil, there was a significant reduction (P<0.05) in whole eye (total), corneal, higher order, and astigmatic wavefront aberrations. A significant difference (P<0.05) in total coma and total spherical aberration after CXL was also observed. Mean baseline pupil center pachymetry and total corneal volume decreased significantly (P<0.05) to 470.09+/-29.01 microm and 57.17+/-3.21 mm(3) from baseline values of 490.68+/-30.69 microm and 59.37+/-4.36 mm(3), respectively. Endothelial cell counts did not changed significantly (P=0.13).

Conclusions: Corneal cross-linking seems to be effective in improving UCVA and BSCVA in eyes with progressive keratoconus by significantly reducing corneal APP, AK, and corneal and total wavefront aberrations at 1 year postoperatively.

Citing Articles

Topography-guided photorefractive keratectomy combined with accelerated corneal collagen cross-linking versus cross-linking alone for progressive keratoconus: a long-term prospective cohort study.

Dai Z, Liu Z, Zhang Y, Yuan Y, Liu Y, Wang Y Front Med (Lausanne). 2024; 11:1420264.

PMID: 39188874 PMC: 11345261. DOI: 10.3389/fmed.2024.1420264.


Combined topography-guided photorefractive keratectomy and corneal collagen crosslinking.

Kumar K, Nataraj S, Maganty V, Porwal K, Gangasagara S Indian J Ophthalmol. 2024; 72(Suppl 4):S639-S644.

PMID: 38767551 PMC: 11338431. DOI: 10.4103/IJO.IJO_791_23.


Corneal collagen cross-linking in patients with keratoconus from the Dresden protocol to customized solutions: theoretical basis.

Caruso C, DAndrea L, Troisi M, Rinaldi M, Piscopo R, Troisi S Int J Ophthalmol. 2024; 17(5):951-962.

PMID: 38766341 PMC: 11074195. DOI: 10.18240/ijo.2024.05.21.


Corneal Collagen Crosslinking for Ectasia After Refractive Surgery: A Systematic Review and Meta-Analysis.

Amaral D, Menezes A, Lima L, Faneli A, Neto P, Canedo A Clin Ophthalmol. 2024; 18:865-879.

PMID: 38525385 PMC: 10960511. DOI: 10.2147/OPTH.S451232.


The effect of transepithelial corneal collagen cross-linking treatment on optical quality of the cornea in keratoconus: 12-month clinical results.

Kaya Ergen S, Subasi S, Yilmaz Tugan B, Yuksel N, Altintas O Int Ophthalmol. 2024; 44(1):146.

PMID: 38499839 DOI: 10.1007/s10792-024-03089-7.